期刊文献+

健康志愿者单次口服国产泛昔洛韦片后的药代动力学 被引量:3

Pharmacokinetics of famciclovir after single dosing in Chinese healthy volunteers
下载PDF
导出
摘要 目的 : 研究我国男性健康志愿者单次口服国产泛昔洛韦片后的药代动力学行为 ,并与英国产同类制剂作比较 ,求得相对生物利用度。方法 :  8例男性健康志愿者以四阶优化拉丁方设计分别交叉单次口服英国产及三个剂量的国产泛昔洛韦片 ,在 0~ 2 4h内 11个时间点采集血浆及分段尿液 ,高效液相法测定血、尿中的喷昔洛韦浓度 ,并用 3P87程序计算药代动力学参数和相对生物利用度。结果 : 口服泛昔洛韦片后 ,药物在体内的动力学表现为二室模型 ,三个受试剂量的药代动力学参数与英国产制剂及文献数据基本一致。结论 : 受试药与对照药的药代动力学基本相同 ,受试药的相对生物利用度平均值为 110 .87%。 Objective:To study the pharmacokinetics of domestic and imported famciclovir after single dosing in Chinese healthy male volunteers, and to calculate the relative bioavailability of domestic famciclovir.Methods:Eight healthy male volunteers received single oral doses of famciclovir made in China or U.K. (125 mg,250 mg,500 mg,250mg) according to a latin square cross over design. The plasma and urine levels of penciclovir were determined by HPLC. The data of plasma concentrations of penciclovir were treated with 3P87, and the pharmacokinetic parameters were obtained.Results:After oral administration pharmacokinetic model was described open two compartmental model. The pharmacokinetic parameters of domestic famciclovir were the same as the impored famciclovir. Conclusion :There was no difference between domestic and impooted famciclovir in pharmacokinetics. The relative bioavailability of famciclovir made in China was 110.87%. [
出处 《中国麻风皮肤病杂志》 北大核心 2000年第4期223-225,共3页 China Journal of Leprosy and Skin Diseases
关键词 泛昔洛韦 喷昔洛韦 药代动力学 相对生物利用度 抗病毒药 famciclovir penciclovir pharmacokinetics relative bioavailability
  • 相关文献

参考文献7

  • 1Boyd MR,Safrin S,Kern ER.Penciclovir:a review of its spectrum of activity,selectivity,and cross-resistance pattern.Antiviral Chem Chemother,1993,4(Suppl 1) :3
  • 2Vere Hodgee RA,Cheng YC.The mode of action of penciclovir.Antiviral Chem Chemother,1993,4(Suppl 1):13
  • 3Weinberg AA,Bate BJ,Masters HB.In vitro activities of penciclovir and acyclovir against herpes simplex virus types 1 and 2.Antimicrob Agents Chemother,1992,36 ( 9 ):2037
  • 4Pue MA,Benet LZ.Pharmacokinetics of famciclovir in man.Antiviral Chem Chemother,1993,4( Suppl 1 ) :47
  • 5Bioke SC,Pue MA,Audet PR,et al.Pharmacokinetics of famciclovir in subjects with chronic hepatic disease.J Clin Pharmacol,1994,34(12):1199
  • 6Caroline MP,Antona JW.Famciclovir,a review of its pharmacological properties and therapeutic efficacy in herpesvirus infections.Drugs,1995,50(2) :396
  • 7Fowles SE,Pue MA,Piereeece D,et al.Pharmacokinetics of famciclovir in healthy elderly subjects following a single oral administration of 750 mg famciclovir.Br J Clin Pharmacol.1992,34:450

同被引文献19

  • 1Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines ,2006 [ J ]. MMWR ,2006,55 ( 11 ) : 18 - 19.
  • 2Cernik C, Gallina K, Brodell RT. The treatment of herpes simplex infections : an evidence-based review [ J ]. Arch Intern Med,2008,168 ( 11 ) : 1137 -1144.
  • 3Aoki FY, Tyfing S, Diaz-Mitoma F, et al. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial[ J ]. Clin Infect Dis, 2006,42 (1):8-13.
  • 4Abudalu M, Tyring S, Koltun W, et al. Single-day, patient-initiated famciclovir therapy versus 3-day valacyclovir regimen for recurrent genital herpes : a randomized, double-blind, comparative trial [ J ]. Clin Infect Dis ,2008 ,47 (5) :651 - 658.
  • 5Tyring S, Richwald G, Hamed K. Single-day therapy: an expert opinion on a recent development for the episodic treatment of recurrent genital herpes[ J]. Arch Gynecol Obstet,2007,275 ( 1 ) : 1 - 3.
  • 6Brown ZA, Kern ER, Spruance SL, et al. Clinical and virologic course of herpes simplex genitalis[ J]. West J Med, 1979,130(5) :414 -421.
  • 7Faro S. A review of famciclovir in the management of genital herpes [J]. Infect Dis Obstet Gynecol, 1998,6( 1 ) :38 -43.
  • 8Saltzman R, Jurewicz R, Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes [ J ]. Antimicrob Agents Chemother, 1994,38(10) :2454 -7.
  • 9Langley RG. Famciclovir for the treatment of recurrent genital and labial herpes lesions [ J ]. Skin Therapy Lett, 2005 Dec-2006 Jan, 10 (10) :5 -7.
  • 10Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2006 [J]. MMWR 2006, 55 (No. RR- 11) :19.

引证文献3

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部